Form 4: Vor Biopharma Director Receives Stock Option Grant

Director Wouter Joustra was granted 57,162 stock options in Vor Biopharma Inc. as part of a standard equity compensation plan.

Summary

• Director Wouter Joustra acquired 57,162 stock options in Vor Biopharma Inc. (VOR).
• The options have an exercise price of $14.09 per share.
• The grant was issued on June 11, 2026, with an expiration date of June 10, 2036.
• Vesting occurs in 36 equal monthly installments starting July 11, 2026, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is subject to the continued service of the director, which is not guaranteed.

Future Outlook

The options vest over a three-year period, indicating a long-term commitment to the company's performance.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership retention and alignment with clinical development milestones.

Comparison to Industry Standards

• The vesting schedule of 36 months is consistent with standard corporate governance practices for board members in the life sciences industry.
• The use of stock options as a primary incentive tool is common among mid-cap and small-cap biotech firms to preserve cash reserves.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Director to continue service to satisfy the monthly vesting requirements.

Key Dates

Keywords

Vor Biopharma, VOR, SEC Form 4, Insider Trading, Stock Options, Biotech, Equity Compensation